報價延遲最少15分鐘:2026/03/31 16:48 EDT
盤後時段
|
||||
|
2.32 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.34
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.91/-1.80
|
|
企業價值
174.27M
|
| 資產負債 |
|
每股賬面淨值
3.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
